[go: up one dir, main page]

EA201100441A1 - Соединения для коррекции уровня мочевой кислоты и способы их применения - Google Patents

Соединения для коррекции уровня мочевой кислоты и способы их применения

Info

Publication number
EA201100441A1
EA201100441A1 EA201100441A EA201100441A EA201100441A1 EA 201100441 A1 EA201100441 A1 EA 201100441A1 EA 201100441 A EA201100441 A EA 201100441A EA 201100441 A EA201100441 A EA 201100441A EA 201100441 A1 EA201100441 A1 EA 201100441A1
Authority
EA
Eurasian Patent Office
Prior art keywords
uric acid
methods
compounds
correction
application
Prior art date
Application number
EA201100441A
Other languages
English (en)
Inventor
Эсмир Гуниц
Жан-Люк Жирарде
Дэвид А. Пейзнер
Original Assignee
Ардеа Биосайнсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ардеа Биосайнсиз, Инк. filed Critical Ардеа Биосайнсиз, Инк.
Publication of EA201100441A1 publication Critical patent/EA201100441A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Раскрываются соединения, полезные для регулирования уровня мочевой кислоты в крови, лекарственные составы, содержащие их, а также методы их изготовления и применения. В некоторых осуществлениях описываемые соединения используются для лечения или предотвращения нарушений, связанных с не соответствующим норме уровнем мочевой кислоты в организме.
EA201100441A 2008-09-04 2009-09-03 Соединения для коррекции уровня мочевой кислоты и способы их применения EA201100441A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9438808P 2008-09-04 2008-09-04
US18011009P 2009-05-20 2009-05-20
PCT/US2009/055947 WO2010028189A2 (en) 2008-09-04 2009-09-03 Compounds, compositions and methods of using same for modulating uric acid levels

Publications (1)

Publication Number Publication Date
EA201100441A1 true EA201100441A1 (ru) 2011-10-31

Family

ID=41726354

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201100441A EA201100441A1 (ru) 2008-09-04 2009-09-03 Соединения для коррекции уровня мочевой кислоты и способы их применения
EA201100440A EA023500B1 (ru) 2008-09-04 2009-09-03 Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201100440A EA023500B1 (ru) 2008-09-04 2009-09-03 Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты

Country Status (15)

Country Link
US (3) US8193234B2 (ru)
EP (2) EP2328874A4 (ru)
JP (3) JP2012502050A (ru)
KR (2) KR101294872B1 (ru)
CN (3) CN103819419B (ru)
AR (1) AR073548A1 (ru)
AU (2) AU2009289647C1 (ru)
BR (1) BRPI0918586A2 (ru)
CA (2) CA2735828C (ru)
EA (2) EA201100441A1 (ru)
IL (2) IL211429A (ru)
MX (2) MX2011002450A (ru)
TW (2) TW201018463A (ru)
WO (2) WO2010028189A2 (ru)
ZA (3) ZA201101626B (ru)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2472374C (en) 2001-12-05 2012-02-14 Sagax, Inc. Endovascular device for entrapment of particulate matter and method for use
JP2012502050A (ja) * 2008-09-04 2012-01-26 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及びそれを使用する方法。
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
WO2010135536A2 (en) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Methods of modulating uric acid levels
ES2563207T3 (es) * 2010-01-08 2016-03-11 Ardea Biosciences, Inc. Formas polimorfas, cristalinas y en mesofases de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4H-1,2,4-triazol-3-iltio)acetato de sodio y sus usos
EP3659601A1 (en) * 2010-03-30 2020-06-03 Ardea Biosciences, Inc. Treatment of gout
EP2582683B1 (en) * 2010-06-15 2018-03-21 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
JP5709146B2 (ja) 2010-06-16 2015-04-30 アルデア バイオサイエンシーズ インク． フェニルチオ酢酸化合物、組成物、および、その使用方法
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
ES2614914T3 (es) * 2010-12-30 2017-06-02 Ardea Biosciences, Inc. Formas polimórficas de ácido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4H-1,2,4-triazol-3-iltio)acético y usos de las mismas
UA109943C2 (xx) * 2011-05-24 2015-10-26 Гіпертонія й гіперурикемія
AU2012332154B2 (en) 2011-11-03 2016-11-17 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
AR091651A1 (es) * 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
ME03016B (me) * 2012-11-14 2018-10-20 Teijin Pharma Ltd Derivat piridina
CN103389346B (zh) * 2013-07-18 2014-08-06 湖北华世通潜龙药业有限公司 利用hplc测定非布司他及口服制剂中有关物质的方法
CN103588716A (zh) * 2013-11-22 2014-02-19 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的新晶型及其制备方法
EP3071554B1 (en) * 2013-11-22 2018-10-03 Crystal Pharmatech Co., Ltd. Crystalline forms of lesinurad
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
CN104292176B (zh) * 2014-10-07 2016-06-29 张远强 一种含卤代苯的四氮唑乙酸类化合物、其制备方法和用途
CN104292177B (zh) * 2014-10-07 2016-08-17 张远强 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途
CN104341367B (zh) * 2014-10-07 2016-08-17 张远强 一类四氮唑乙酸类化合物、其制备方法及用途
CN104292175B (zh) * 2014-10-07 2016-06-22 张远强 含硝基的四氮唑乙酸类化合物、其制备方法及用途
CN104292178B (zh) * 2014-10-07 2016-06-22 张远强 含四氮唑乙酸类化合物、其制备方法及用途
CN104262276B (zh) * 2014-10-07 2016-06-22 张远强 含卤代苯的四氮唑乙酸类化合物、其制备方法及用途
CN104341363B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104326999B (zh) * 2014-10-27 2017-01-18 张远强 烷氧基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104370843B (zh) * 2014-10-27 2016-05-18 张远强 卤代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341361B (zh) * 2014-10-27 2017-01-11 张远强 一种腈基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341362B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104341364A (zh) * 2014-10-27 2015-02-11 张远强 三氮唑丙二酸类化合物、其制备方法及用途
CN104326998B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104327000B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104356078A (zh) * 2014-10-27 2015-02-18 张远强 卤代三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104341365A (zh) * 2014-10-27 2015-02-11 张远强 卤代三氮唑丙二酸类化合物、其制备方法及用途
CN104370842B (zh) * 2014-10-27 2016-07-13 张远强 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104326997B (zh) * 2014-10-27 2016-09-21 张远强 烷氧基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104326993B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104326995A (zh) * 2014-10-27 2015-02-04 张远强 一种腈基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104326996A (zh) * 2014-10-27 2015-02-04 张远强 一种硝基取代三氮唑丙二酸类化合物、其制备方法及用途
CN104370841B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104311498B (zh) * 2014-10-27 2016-04-06 张远强 烷氧基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104326994A (zh) * 2014-10-27 2015-02-04 张远强 一种腈基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
KR20170110083A (ko) 2014-12-23 2017-10-10 인털렉츄얼 프라퍼티 어쏘시에이츠, 엘엘씨 경피 투여를 위한 방법 및 제형
AU2015373089B2 (en) 2014-12-29 2020-02-20 Dethree Res. Lab. Inc. URAT1 inhibitor
CN104817562B (zh) * 2015-04-17 2017-05-03 东南大学 一种具有治疗及预防高尿酸血症或痛风的化合物及其制备方法和应用
CN106187926B (zh) * 2015-04-30 2018-11-27 天津药物研究院有限公司 含二芳基甲烷结构的羧酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
WO2017028762A1 (zh) * 2015-08-14 2017-02-23 广东东阳光药业有限公司 一种萘环化合物的晶型
KR102244216B1 (ko) * 2016-05-23 2021-04-26 메드샤인 디스커버리 아이엔씨. 티오펜 화합물 및 이의 합성 방법과 이의 의약에서의 용도
EP3473617B1 (en) * 2016-06-17 2022-09-07 Medshine Discovery Inc. Halogenated compound and axially chiral isomers thereof
CN107540619B (zh) 2016-06-29 2019-08-16 天津药物研究院有限公司 一种尿酸转运体1抑制剂的制备方法
CN107814795B (zh) * 2016-09-12 2020-12-18 江苏艾立康药业股份有限公司 作为urat1抑制剂的化合物
CN108658879A (zh) * 2017-03-29 2018-10-16 天津药物研究院有限公司 一种urat1抑制剂及其制备方法和用途
US20190083386A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of buffering agents
CN109134391A (zh) * 2018-09-21 2019-01-04 山东大学 一种酰基磺酰胺类衍生物及其制备方法与应用
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN111763218B (zh) * 2020-07-14 2021-05-28 山东大学 一种噻吩并嘧啶酮巯乙酸类衍生物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2009A (en) * 1841-03-18 Improvement in machines for boring war-rockets
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
NL7112373A (ru) * 1970-09-25 1972-03-28
US4198513A (en) 1970-09-25 1980-04-15 Merck & Co., Inc. 1,2,4-Triazoles
US4935438A (en) * 1987-12-29 1990-06-19 Smithkline Beckman Corporation Dopamine-β-hydroxylase inhibitors
WO1998035957A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
GB0028702D0 (en) * 2000-11-24 2001-01-10 Novartis Ag Organic compounds
AU2003295324B2 (en) * 2002-08-23 2008-08-28 Ardea Biosciences,Inc. Non-nucleoside reverse transcriptase inhibitors
US7642277B2 (en) * 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
CN1934095A (zh) * 2004-03-08 2007-03-21 惠氏公司 离子通道调节剂
CN1946397A (zh) * 2004-03-08 2007-04-11 惠氏公司 离子通道调节剂
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
MX2007002236A (es) * 2004-08-25 2007-07-09 Ardea Biosciences Inc S-triazolil-alfa-mercaptoacetanilidas como inhibidores de transcriptasa inversa de virus de inmunodeficiencia humana.
WO2006091506A2 (en) * 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y4 receptor agonists
CA2653336C (en) 2006-05-25 2014-10-28 Synta Pharmaceuticals Corp. Method for treating non-hodgkin's lymphoma
US20100280032A1 (en) 2006-10-26 2010-11-04 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
SG183721A1 (en) * 2007-11-27 2012-09-27 Ardea Biosciences Inc Novel compounds and compositions and methods of use
JP2012502050A (ja) 2008-09-04 2012-01-26 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及びそれを使用する方法。
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
WO2010135530A2 (en) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Compounds, compositions and methods for modulating uric acid levels

Also Published As

Publication number Publication date
TWI377200B (en) 2012-11-21
KR20110050708A (ko) 2011-05-16
JP2015042647A (ja) 2015-03-05
MX2011002449A (es) 2011-05-25
US20130040963A1 (en) 2013-02-14
US8344012B2 (en) 2013-01-01
US20100056542A1 (en) 2010-03-04
AU2009289646A1 (en) 2010-03-11
ZA201203779B (en) 2014-01-29
WO2010028189A2 (en) 2010-03-11
WO2010028189A3 (en) 2010-06-17
CN102186832B (zh) 2014-04-02
ZA201101626B (en) 2012-08-29
AU2009289646B2 (en) 2012-07-05
EP2328874A2 (en) 2011-06-08
BRPI0918586A2 (pt) 2015-12-01
EP2328879A2 (en) 2011-06-08
IL211429A (en) 2014-09-30
CA2736117C (en) 2013-11-19
TW201018463A (en) 2010-05-16
US20100056593A1 (en) 2010-03-04
EP2328874A4 (en) 2012-05-09
JP2012502050A (ja) 2012-01-26
CN103819419A (zh) 2014-05-28
CN103819419B (zh) 2016-12-07
AR073548A1 (es) 2010-11-17
AU2009289647A1 (en) 2010-03-11
IL211428A0 (en) 2011-05-31
IL211429A0 (en) 2011-05-31
CA2735828A1 (en) 2010-03-11
AU2009289647B2 (en) 2012-09-20
TW201022216A (en) 2010-06-16
KR20110050709A (ko) 2011-05-16
EA201100440A1 (ru) 2011-10-31
CN102186832A (zh) 2011-09-14
EP2328879A4 (en) 2012-05-09
CA2736117A1 (en) 2010-03-11
MX2011002450A (es) 2011-05-25
WO2010028190A2 (en) 2010-03-11
KR101294872B1 (ko) 2013-08-08
CN102186827A (zh) 2011-09-14
CA2735828C (en) 2013-07-23
EA023500B1 (ru) 2016-06-30
WO2010028190A3 (en) 2010-07-01
AU2009289647C1 (en) 2013-03-21
JP5918327B2 (ja) 2016-05-18
ZA201204031B (en) 2014-02-26
JP2012502049A (ja) 2012-01-26
US8193234B2 (en) 2012-06-05
HK1160843A1 (en) 2012-08-17

Similar Documents

Publication Publication Date Title
EA201100440A1 (ru) Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
EA201000897A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
EA201170349A1 (ru) Модуляторы mif
EA202091708A1 (ru) Ингибиторы днк-пк
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201790267A1 (ru) Новые модуляторы киназ
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
UA110612C2 (ru) Производные 1-амино-2-циклопропилетилбороновои кислоты
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
WO2010135530A3 (en) Compounds, compositions and methods for modulating uric acid levels
EA201290860A1 (ru) Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201200952A1 (ru) Производные пиразина и их применение для лечения неврологических нарушений
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119